Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Narrative (Details)

v3.23.1
Revenue Recognition - Narrative (Details)
$ in Millions
3 Months Ended
Mar. 31, 2023
USD ($)
segment
Mar. 31, 2022
USD ($)
Revenue from Contract with Customer [Abstract]    
Number of operating segments | segment 2  
Pharma contract liability, revenue recognized $ 1.8 $ 3.1
Amortization of contract commissions $ 0.2 $ 0.1